NCT01861795

Brief Summary

The purpose of this observational study is to collect data on vital signs, oxygen requirements and other data related to ventilator care in preterm neonates under standard of care treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2013

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 26, 2013

Completed
28 days until next milestone

First Posted

Study publicly available on registry

May 24, 2013

Completed
8 days until next milestone

Study Start

First participant enrolled

June 1, 2013

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
Last Updated

August 22, 2014

Status Verified

August 1, 2014

Enrollment Period

9 months

First QC Date

April 26, 2013

Last Update Submit

August 20, 2014

Conditions

Keywords

Drug therapy

Outcome Measures

Primary Outcomes (1)

  • Time and failure-adjusted Area Under the Curve (AUC) from Time 0 (T0) to 98 hours after T0 (T47) (AUCT0-T47adjusted) of fraction of inspired oxygen (FiO2)

    Fraction of inspired oxygen (FiO2) is the amount of oxygen in the ventilator outlet gas flow.

    Beginning of the Intensive observation phase (T0; approximately 45 minutes after birth) to 98 hours after T0

Secondary Outcomes (13)

  • Time with optimal saturation of peripheral oxygen (SpO2) of 88% to 96%

    T0 and at 0.25, 0.5, 0.75 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75 4, 4.25. 4.5, 4.74, 5, 5.25, 5.75, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, and 54 hours

  • Continuous positive airway pressure (CPAP)-failure necessitating intubation and mechanical ventillation and/or surfactant instillation during observation period from T0 to 98 hours

    T0 to 98 hours

  • Percentage of participants requiring instillation of an approved surfactant preparation

    Gestational week (GW) 36+6 days

  • Percentage of participants with bronchopulmonary dysplasia (BPD) at GW 36

    Gestational Week 36

  • Respiratory rate over time

    T0 to Gestational Week 36

  • +8 more secondary outcomes

Study Arms (1)

Preterm Neonates

Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.

Other: Preterm Neonates

Interventions

Preterm Neonates

Preterm Neonates

Eligibility Criteria

Age27 Weeks - 36 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Preterm neonates on non-invasive ventilatory support in a hospital setting.

You may qualify if:

  • \. Written, informed consent of both parents or legal guardian(s) obtained (on admission, prior to or after delivery).
  • \. Preterm neonates born at or above 27+0 gestational weeks (GW) who are sufficiently stable on nasal continuous positive airway pressure (CPAP). Upper limit 36+0 GW.
  • \. Participants' minimum weight at birth must be 800 g. Upper weight limit is 2500 g.
  • \. CPAP-positive end-expiratory pressure (PEEP) must be ≥5 cm and ≤ 8 cm H2O. 5. Fraction of oxygen (O2) in ventilator outlet gas flow (FiO2) ≥ 30% to reach saturation goal (SpO2 between 88% and 96%) during the time period from B0 to T0.

You may not qualify if:

  • \. FiO2 \> 50% to reach saturation goal (saturation of peripheral oxygen (SpO2) between 88% and 96%) during the time period from 30 minutes after birth (B0) to 45 minutes after birth (T0).
  • \. Presence of severe respiratory distress syndrome (RDS) necessitating immediate intubation and surfactant rescue at entry into the study, or having necessitated surfactant rescue prior to entry into the study.
  • \. Known life-threatening congenital anomaly or genetic syndrome. 4. Participation in an interventional study in parallel to this observational study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Unknown Facility

Hanover, Germany

Location

Unknown Facility

Lübeck, Germany

Location

Unknown Facility

Nuremberg, Germany

Location

MeSH Terms

Conditions

Pulmonary Atelectasis

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Study Officials

  • Medical Director

    Takeda

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 26, 2013

First Posted

May 24, 2013

Study Start

June 1, 2013

Primary Completion

March 1, 2014

Study Completion

March 1, 2014

Last Updated

August 22, 2014

Record last verified: 2014-08

Locations